Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSDecember 9th, 2019: FUJIFILM Toyama Chemical Co., Ltd. announced that it has completed its first manufacturing facility named 701 for liposome formulation in Japan.
June 17th, 2020: Ipsen Pharma announced that it has received the Fast Track designation by the United States Food and Drug Administration (FDA) for the investigational use of liposomal irinotecan (ONIVYDE) in combination with oxaliplatin (OX) and 5-fluorouracil/leucovorin (5-FU/LV) together.
The global liposome drug delivery market is estimated to garner a revenue of USD 11977.1 Million by the end of 2031 by growing at a CAGR of 10.69% over the forecast period, i.e., 2022 – 2031. Moreover, in the year 2021, the market generated a revenue of USD 4356.7 Million. The growth of the market can be attributed to the rising prevalence of cancer, and therefore the need for advanced drug delivery systems for the treatment of the disease. Cancer is known to be one of the leading causes of death around the globe according to the World Health Organization (WHO). Moreover, the WHO also stated that in the year 2020, nearly 10 Million deaths were caused as a result of cancer. With several research and development activities happening worldwide for the development of drugs and drug delivery devices for the treatment of cancer, liposomes have been shown to be particularly beneficial in the treatment of the chronic disease. Liposomes, which are a novel drug delivery system (NDDS), are known to reduce the harmful effects of chemotherapeutic drugs. On the other hand, the rising focus of the healthcare researchers on developing targeted drug delivery systems (TDDS) is also expected to create numerous opportunities for market growth. Besides this, the surge in use of liposomes as a drug delivery system is also expected to contribute to the growth of the market during the forecast period.
Get more information on this report: Request Sample PDF
Regionally, the global liposome drug delivery market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is projected to garner the largest revenue of USD 4429.6 Million by the end of 2031, up from a revenue of USD 1689.9 Million in the year 2021. The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems, along with the surge in healthcare expenditure in the region. According to the statistics by the National Cancer Institute (NCI), in the year 2020, the new cases of cancer that was expected to be diagnosed in the United States was about 1806590 cases. The statistics also stated that during the same year 606520 people were expected to die as a result of the disease.
On the other hand, the market in Europe is projected to garner the second-largest revenue of USD 4213.1 Million by the end of 2031, up from a revenue of USD 1500.9 Million in the year 2021. The market in the region is further segmented by country into Germany, France, United Kingdom, Italy, Spain, and the Rest of Europe. The market in Germany is projected to garner the second-largest revenue of USD 828.4 Million by the end of 2031, up from a revenue of USD 276.2 Million in the year 2021.
The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
The global liposome drug delivery market is segmented by product into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. The liposomal doxorubicin segment is projected to garner the largest revenue of USD 3218.1 Million by the end of 2031, up from a revenue of USD 1142.1 Million in the year 2021. By technology, the market is segmented by technology into stealth liposome technology, non-PEGylated liposome technology, and DepoFoam liposome technology. Out of these, the stealth liposome technology segment is projected to garner the largest revenue of USD 5181.3 Million by the end of 2031, up from a revenue of USD 1910.0 Million in the year 2021. By application, the market is segmented into fungal diseases, pain management, cancer therapy, viral vaccines, photodynamic therapy, and others. The cancer therapy segment is projected to garner the largest revenue of USD 5538.8 Million by the end of 2031, up from a revenue of USD 2024.5 Million in the year 2021.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global liposome drug delivery market that are included in our report are Spectrum Pharmaceuticals, Inc., Gilead Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc., Astellas Pharma Inc., Elan Pharmaceuticals (Perrigo Company plc), Merrimack Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., and others. Besides this, some of the prominent raw material manufacturers in the global liposome drug delivery market that are included in our report are NIPPON FINE CHEMICAL CO., LTD., Sonic Biochem Extractions Pvt. Ltd., Croda International Plc, Lipoid GmbH, Hashimoto Electronic Industry Co., LTD, and others.
FREQUENTLY ASKED QUESTIONS
The rising prevalence of cancer globally, and the increasing application of liposomes as a drug delivery system are some of the major factors anticipated to drive the market growth.
The market is anticipated to attain a CAGR of 10.69% over the forecast period, i.e., 2022 – 2031.
The high cost of development of the drug delivery system is one of the major factors estimated to hamper the market growth.
The market in North America is projected to garner the largest revenue of USD 4429.6 Million by the end of 2031 and provide more business opportunities in future.
Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, technology, application, and by region.
The liposomal doxorubicin segment is projected to garner the largest revenue of USD 3218.1 Million by the end of 2031 and display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
